New publication: Retrospective analysis of 131 stage IV cancer patients treated with a combined protocol of low-dose checkpoint inhibitors, IL-2, and hyperthermia

In Cancer Immunology, Immunotherapy R. Kleef et al. have just published the paper

"Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution".

The publication is "open access":

Treatment consisted of locoregional- and whole-body hyperthermia, individually dose adapted interleukin 2 (IL-2) combined with low-dose ipilimumab (0.3 mg/kg) plus nivolumab (0.5 mg/kg). Fever-range whole-body hyperthermia was conducted with heckel-HT3000.

The authors conclude that "the immune-related adverse events profile of the combined treatment is safer than that of the established protocols without compromising efficacy".

Good response rates were observed even in cancer entities where immunotherapy has not yet been established as standard therapy.


Fig. 1 Detailed history and chest X-rays of a patient with triple-negative breast cancer from diagnosis and treatment before (a) and after attending (b) the outpatient clinic with the respective regimen. Long-term follow-up is also displayed supported by chest X-rays.

Print Email

heckel medizintechnik GmbH

Olgastrasse 25
73728 Esslingen

Tel: ++49 (0)711 - 128989 - 0


Visit us on Facebook

Visit us on Linkedin





We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.